LB Pharmaceuticals

aid: lb-pharmaceuticals
name: LB Pharmaceuticals
description: 'LB Pharmaceuticals Inc (Nasdaq: LBRX) is a clinical-stage biopharmaceutical company headquartered at One Pennsylvania
  Plaza, New York, developing novel therapies for neuropsychiatric diseases including schizophrenia and bipolar depression.
  Its lead asset, LB-102, is an oral small-molecule benzamide antipsychotic with potent D2, D3 and 5HT7 antagonism, positioned
  to become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States. The company reported
  positive Phase 2 schizophrenia results from its NOVA1 trial in January 2025 and initiated the ILLUMINATE-1 Phase 2 bipolar
  depression trial in January 2026. LB Pharmaceuticals is a drug developer, not a software vendor: it publishes no public
  API, developer portal, SDK or machine-readable contract, and its web presence is a WordPress corporate and investor-relations
  site.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://lbpharma.us/wp-content/uploads/2026/03/LBlogo-color_final-opt.png
url: https://raw.githubusercontent.com/api-evangelist/lb-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-10-06'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Health
- Clinical Trials
- Neuroscience
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- url: https://ir.lbpharma.us/investors/news/
  type: Blog
- type: DomainSecurity
  url: security/lb-pharmaceuticals-domain-security.yml
- type: Website
  url: https://lbpharma.us/
- type: PrivacyPolicy
  url: https://lbpharma.us/privacy-policy/
- type: Support
  url: https://lbpharma.us/contact/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: LB Pharmaceuticals is a clinical-stage drug developer whose entire web presence is a WordPress marketing and investor-relations
    site; the only machine-readable surface is the stock WordPress core REST API at lbpharma.us/wp-json/ (222 routes, every
    namespace a CMS plugin such as contact-form-7, redirection and wp-smush), with no product API, no developer or docs subdomain
    (api./docs./developer.lbpharma.us all NXDOMAIN), no GitHub organization and no published client library.
  evidence:
  - url: https://lbpharma.us/wp-json/
    status: 200
  - url: https://lbpharma.us/openapi.json
    status: 404
  - url: https://lbpharma.us/.well-known/agent-card.json
    status: 404
  - url: https://api.github.com/orgs/lbpharma
    status: 404
  checked: '2026-08-23'